Abbott Laboratories shares have fallen from $127.12 to $90.53 due to sector-wide rotation and concerns over its $21 billion Exact Sciences acquisition. Despite this, its diabetes franchise, led by the FreeStyle Libre glucose monitor, and medical devices unit are growing strongly, with CGM sales up 13.8% and medical devices revenue up 13.2%. Abbott's forward P/E is 16, and analysts see upside to a $116.54 target, with 20 out of 27 rating it a Buy or Strong Buy. Risks include integration costs and competition, but the stock offers a 2.76% dividend yield and potential growth from expanding diabetes treatment markets. Investors may wait for Q2 earnings on July 20, 2026, to confirm growth momentum before buying.
The global bloodstream infection testing market is projected to grow from $876.49 million in 2025 to $1.4 billion by 2035, at a CAGR of 4.8%. Growth is fueled by rising bloodstream infection cases, increased sepsis hospitalizations, and wider adoptio...
Abbott will announce its financial results for the second quarter of 2026 on July 16 before the market opens. The company will host a live webcast of the earnings call at 8 a.m. Central time, accessible via its Investor Relations website. Abbott is a...
Abbott Laboratories reported solid Q1 2026 results with revenue growth driven by its diversified healthcare segments, including a 13.2% rise in Medical Devices and a recent $21 billion acquisition of Exact Sciences to boost diagnostics. The company h...
ALZpath Inc. has signed a licensing agreement with Abbott to integrate its proprietary pTau217 antibody into an in vitro diagnostic test for Alzheimer's disease. This test will be developed for Abbott's widely used Alinity ci-series systems, enabling...
MiniMed has commercially launched its MiniMed 780G system integrated with Abbott's Instinct sensor and the MiniMed Go system integrated with the Instinct Go sensor in Europe. These sensors are the smallest and longest-wear options from Abbott, enhanc...
